Summit Therapeutics Share Discussion Threads

[football] 06/10/2016 18:34

patviera odd you only turn up when the share price is falling and go missing when its blue?

[patviera] 06/10/2016 17:30

NeoAre you stalking me?!!If you want to make some money NeoWait for Spsy to drift and buy some sub 25pThese have 20p in cash and a great growth business I have a 100p target

[luminoso] 06/10/2016 17:19

lively over the water as usual.

[luminoso] 06/10/2016 17:18

Good posts, waterloo. Only thing I would add is that the Takeover option is always there for the future, either by Sarepta or another entity, and if the trials are looking good, that may realise much much more than £5 either end 2017/ 2018. Things can move very quickly indeed as we have seen in the last two weeks or so since SRPT's approval.

[chrisatrdg] 06/10/2016 16:51

Sarepta Pivots To Business Development - see link below:

[waterloo01] 06/10/2016 16:42

It will settle soon (SP that is). Traders will move on and it will find it's price. Interesting that the majority of brokers are now between $28/$30 12 month target (no doubt revised once we know about C.diff).

I'm still of the view that RDZ underwrites the market cap, to what extent and at what level will be clearer post RDZ updates, but the broker notes talk of $1bn in sales by 2021.

I'm delighted overall that they are now funded to at least 2018 without recall to shareholders and have derisked in DMD. The size of the prize remains huge, not only in milestones and royalties but in having kept the US market. I look forward to some broker numbers highlighting it, but the US market is probably worth more than the rights we have sold so far!

Edit: Long way to go but if we keep a decent % of RDZ and into it's phase 3's by mid-2017 and we get positive readout from the current trial, £5.00 a share on AIM seem quite possible within 12 months (ie current broker target).

[sorrento06] 06/10/2016 16:24

Friday 12:00 - C-Diff deal. ; ) DYOR!

[hugus maximus] 06/10/2016 16:15

But the NASDAQ is having a painful day too ... that's not our MMs.

[chrisatrdg] 06/10/2016 15:59

Two large Buys just posted 25,000 at 208 & 21,667 at 205 - I think HM was right.

[jag63] 06/10/2016 15:53

Usually drops before positive news?....let's hope for a bounce back soon. I'm not worried, if it drops any further will top up again

[hugus maximus] 06/10/2016 15:46

SP currently sub £2.00 ... someone must be filling an order book .. this is ridiculous?

[hugus maximus] 06/10/2016 15:35

Fascinating note here from SeekingAlpha about Sarepta / Summit deal (with the "newly appointed Glyn Edwards" .. journalism not quite what it used to be?!)

I found much of interest here:

"<<<<For Summit the $40m is an unexpected windfall, and vindicates its transformation from a drug-screening company and developer of a mixed bag of early-stage projects arising from the University of Oxford, under its former name of Vastox, to its current focus on DMD under a new chief executive, Glyn Edwards, formerly of Antisoma.

Another voucher?

Sharp-eyed DMD watchers noted with interest the recent granting to Summit’s ezutromid of US pediatric designation, which the group said could translate into a pediatric priority review voucher (PRV) if ezutromid received FDA approval.

Pediatric PRVs have become prominent because they can be transferred to another company. They have sold for as much as $350m, though the most recent one seems to have gone for around $200m (Priority review vouchers revisited, September 22, 2016).

The legislation governing this scheme was expected to have been renewed last month, but the decision was deferred until December. Sarepta received a pediatric PRV along with Exondys 51 approval – if the legislation is not renewed this could be a highly valuable asset, since it would be one of only four pediatric PRVs in existence.

Summit told EP Vantage that if the legislation is not renewed then it would no longer qualify for a pediatric PRV on potential approval of ezutromid. It has also said that it saw orphan disease designation as a more important accolade in the near term.

Not mutation-specific

Mechanistically ezutromid is an interesting choice for Sarepta. Unlike Exondys 51 it is an oral small molecule designed to modulate utrophin, a protein related to dystrophin; both these proteins play a role in muscle development, but dystrophin gradually takes over this function from utrophin as muscles mature.

The intriguing aspect is that while Sarepta’s exon-skipping approaches target specific subtypes of DMD, a small-molecule utrophin modulator could in theory target the whole patient population.

While at present ezutromid is being studied as monotherapy, on a call yesterday Mr Edwards also spoke at length about the potential for a combination. Even when dystrophin production is stimulated via exon skipping in DMD it does not occupy all binding sites on the muscle fibre; unfilled sites can then be occupied by utrophin to potentiate the effect.

However, designing a surrogate endpoint is more complicated than was the case with Exondys 51, where Sarepta was to an extent able to demonstrate dystrophin production. Typical DMD patient muscle biopsies already show some utrophin production in response to damage, and the aim is to achieve a more uniform distribution of utrophin, which is hard to demonstrate.

Most likely a new surrogate endpoint will be needed – Mr Edwards suggested MRI or muscle fibre maturity data – for accelerated approval, and then confirmatory data would need to show improvement in one of the functional endpoints such as six-minute walk test or an alternative “less noisy” endpoint.>>>;>"

The complete article here:

[neo26] 06/10/2016 15:31

patty

what price u buy at?

[patviera] 06/10/2016 15:27

Anyone buying sub 200p which is the old 10p will make a lot of moneyI'm v positive at these levels

[neo26] 06/10/2016 15:27

this is taking a battering, why?

[luminoso] 06/10/2016 14:57

Its possible, football. I did some research a while back on him and many of his stated positions seemed to be in a bad way, so assume he might now need the money. However, I relied on historical holding rns's and that may not give a true picture !!

[hugus maximus] 06/10/2016 14:47

Hi Chris .. understand completely your thoughts re: making use of spikes. Although I've been here several years, I haven't followed the modus operandi of many others who regularly sell and buy back in.

I look back at this weeks £2.50 and think now I should have taken some profit. However, I thought that after seeing the rise on AIM in reaction to the news, the NASDAQ would have induced a much more significant rise than it did and then the following day, still expected a more consolidated move up towards perhaps £3?

In terms of the real value of Summit shares post the Sarepta deal, someone pointed to that being around £2.50, the sort of figure that I would have agreed with. I certainly didn't expect the spike to be so short lived and wonder if that's surprised others?

Luninoso's point about Mr Griffiths clearing out the final shelf of his cupboard at a price way above what he must have sold the majority of his stock for, makes total sense. Someone shifted 350,000 shares in one lump as the news pushed the share price up this week.

[football] 06/10/2016 14:38

Didn't someone post RG selling was a bad sign he did the same at 1R and the share price double and the shares turn up in a off shore account, maybe the same thing as happen here too

[luminoso] 06/10/2016 14:14

The other factor that may differentiate the share price reaction here from the US is possibly Richard Griffiths. If he was selling at £1 ish, he'll certainly be selling now IF he has any left.